The dosage of natriuretic peptides improves diagnostic performance in patients with acute dyspnea when combined with clinical elements. The high sensitivity of this test allows reasonably excluding heart failure when the value is normal. Nevertheless, an increased level of this biomarker is not specific of heart failure and can be observed in different pathologies such as renal failure, sepsis or elevated pulmonary arterial pressure. We therefore analyse the diagnostic performance of natriuretic peptide in COPD patients and discuss its use for the detection of heart failure in this population.